NCT04478695View on ClinicalTrials.gov

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

October 23, 2020

Study Completion Date

October 23, 2020

Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Interventions
DRUG

AMG 330

Continuous intravenous (IV) infusion.

DRUG

Pembrolizumab

Intravenous (IV) infusion.

Trial Locations (2)

77030

University of Texas MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Amgen

INDUSTRY

NCT04478695 - Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter